EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate

Ryo Ohashi iD, Shuichi Otake, Tatsuhiko Murata, Ryosuke Watari iD, Shinpei Yoshida, Mikiko Kitade, Daisuke Kondo, Go Kimura

Pharmaceutics · 18.12.2025 · 17 (12) · 1627

DOI: 10.3390/pharmaceutics17121627 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 18.12.2025. Verfasst von Ryo Ohashi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Formulation R&D Laboratory, Pharmaceutical Technology Research Division, Shionogi & Co., Ltd., 1-3 Kuise, Terajima 2-chome, Amagasaki 660-0813, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: S-892216 is a poorly water-soluble drug developed as a novel oral treatment for COVID-19, although its oral absorption is low. For Phase 1 (Ph1) studies and commercial use, both oral solution and solid dispersion technologies are evaluated to enhance drug solubility.

Methods

The solubility enhancement technology was selected by considering physicochemical factors such as stability and oral absorption, along with patient and customer acceptability.

Results

Pharmacokinetics study in rats revealed that both the polyethylene glycol 400 oral solution and polyvinylpyrrolidone-vinyl acetate (PVPVA) amorphous solid dispersion powder suspension showed almost 100% oral bioavailability. Therefore, they can be proposed as clinical formulations for Ph1 studies. PVPVA solid dispersion tablets were developed as a to-be-marketed formulation showed higher bioavailability in dogs than the anhydrous crystal formulation. Additionally, the stability of the developed solid dispersion tablet was acceptable.

Conclusions

This study demonstrates that multiple solubility enhancement technologies can be adopted for S-892216 development, and amorphous solid dispersion technology was selected for commercialization.

Schlagwörter

Stichwörter der Autor:innen

amorphous solid dispersionoral solutionpoorly water-soluble drugsolubility enhancement technologystability

Autor:innen und Institutionen

  • Formulation R&D Laboratory, Pharmaceutical Technology Research Division, Shionogi & Co., Ltd., 1-3 Kuise, Terajima 2-chome, Amagasaki 660-0813, Japan.
  • Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd., 1-1 Futaba-cho 3-chome, Toyonaka 561-0825, Japan.

ORCID-Profile: Ryo Ohashi, Ryosuke Watari

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Ohashi, R., Otake, S., Murata, T., Watari, R., Yoshida, S., Kitade, M., Kondo, D., & Kimura, G. (2025). Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate. Pharmaceutics, 17(12), 1627. https://doi.org/10.3390/pharmaceutics17121627

Vancouver

Ohashi R, Otake S, Murata T, Watari R, Yoshida S, Kitade M, et al. Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate. Pharmaceutics. 2025;17(12):1627. doi:10.3390/pharmaceutics17121627

BibTeX
@article{Ohashi2025,
  author = {Ohashi, Ryo and Otake, Shuichi and Murata, Tatsuhiko and Watari, Ryosuke and Yoshida, Shinpei and Kitade, Mikiko and Kondo, Daisuke and Kimura, Go},
  title = {Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {12},
  pages = {1627},
  doi = {10.3390/pharmaceutics17121627}
}
Kostenlos starten →